High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL). (June 2017) - Wannesson, B.; Remaggi, G.; Intile, D.; Ferrari, L.; Cruset, S.; Fernández, I.; Miodosky, M.; Cugliari, M.S.; Bordone, J.; Pavlovsky, M.A.